Q3 FY26 results, senior management and board changes announced
MEDANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Midcap 150 and 0.3 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Global Health (Medanta) reported Q3 FY26 standalone revenue of Rs 9,402 mn (up 15.7% YoY) and PAT of Rs 799 mn (down 39% YoY). Consolidated revenue rose to Rs 11,210 mn; PAT was Rs 950 mn. PAT was hit by a Rs 352 mn one-time charge for new Labour Codes. Board appointed Mr. Malik Mohd. Ashhab as Head-Diagnostic Services, re-appointed two independent directors, and proposed appointing CMD Dr. Naresh Trehan's daughter Ms. Shonan Purie Trehan as non-executive director, subject to shareholder approval.
Mixed Q3 with revenue growth but PAT dip from Labour Codes charge. Promoter family board addition may draw governance attention.